FDA Clears Abbott's Companion Dx for Pfizer's NSCLC Drug | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Abbott's companion diagnostic kit to detect rearrangements of the anaplastic lymphoma kinase gene in non-small cell lung cancer.

Abbott's Vysis ALK Break Apart FISH Probe is for use with Pfizer's Xalkori (crizotinib) ALK-inhibitor, whose approval was also announced by FDA on Friday after the close of the market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.